Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Rosenzweig_Brian_1000x714_ENV

Brian K. Rosenzweig

Partner

New York +1 212 841 1108

  • About
  • Representative Matters
  • Credentials
  • About

    Brian Rosenzweig is chair of the firm’s Securities and Capital Markets Practice Group. He regularly represents private and public domestic and foreign companies as well as venture capital funds and investment banks in domestic and international capital-raising transactions.

    Brian's practice predominantly involves capital markets transactions, including "going public transactions" such as initial public offerings and de-SPAC mergers as well as follow-on equity offerings, for domestic and foreign private issuers in the life sciences, technology, and financial services industries. He also regularly represents emerging companies and venture capital funds focused on these industries.

    Brian also regularly advises boards and management teams on securities law issues, corporate governance issues and general corporate matters.

    Chambers USA notes "Brian continues to enjoy a great reputation for his capital markets expertise. He maintains a comprehensive practice, centered around the representation of companies and investment banks in varied securities transactions."

    Areas of Expertise

  • Practices and Industries
  • Representative Matters

    Public Capital Raising

    • Represented NewAmsterdam Pharma in its $450 million going public deSPAC merger with Frazier Lifesciences Acquisition Corporation.
    • Represented Selecta BioSciences, Inc. in its $38.7 million follow-on offering of common stock and warrants.
    • Represented BioNTech SE in its $511 million advanced follow-on offering and related rights offering of American Depositary Shares (ADS).
    • Represented Humacyte, Inc. in its $1 billion going public deSPAC merger with Alpha Healthcare Acquisition Corp.
    • Represented Uber Technologies, Inc. in its U.S. IPO on the NYSE and issuance of $500 million of senior unsecured notes.
    • Represented NeuroSense Therapeutics Ltd. in its U.S. IPO.
    • Represented the underwriters in the U.S. IPO of Trevi Therapeutics, Inc.
    • Represented the underwriters in the U.S. IPO and multiple follow-on offerings of ordinary shares of UroGen Pharma Ltd.
    • Represented Lombard Medical, Inc. in its U.S. IPO.
    • Represented the underwriters in multiple public offerings of Repligen Corporation.
    • Represented the underwriters in the U.S. IPO and a follow-on offering of ADS of Nabriva Therapeutics AG.
    • Represented the underwriters in the U.S. IPO and a follow-on offering of Affimed N.V.

    Private Capital Raising / Emerging Companies / Venture Capital

    • Represented RTW Investments in multiple investments, including cross-over rounds, in private life sciences companies.
    • Represented BioNTech SE in a $50 million private placement of ordinary shares to Fosun Pharma, a $113 million private placement of ordinary shares to Pfizer, and a $251 million private placement of ordinary shares and a convertible note to Temasek.
    • Represented Ceptur Therapeutics, Inc. in its $75 million Series A private placement of common stock.

    Areas of Expertise

  • Credentials
    Education
    • Temple University, Beasley School of Law, J.D., 2004
        • cum laude
    • University of Pennsylvania, B.A., 2001
        • cum laude
    Bar Admissions
    • New York
    Accolades
    • Chambers USA, Capital Markets: Debt & Equity (2017-2024)
    • Chambers Global, Capital Markets: Debt & Equity (2023-2025)
    • Legal 500 US, Capital Markets: Equity Offerings (2016)
    • New York Super Lawyers “Rising Star” (2014-2018)

    Areas of Expertise

News and Insights

Events